Actuate Therapeutics, Inc. Common stock · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-28$7.63 RISE2026-04-10$1.72 PEAK2026-05-07$3.34 160d | -77.5% 133d | Missed | Missed | — | — | +94.2% 27d | Missed |
DROP2025-09-04$8.72 RISE2025-11-19$5.85 PEAK2025-11-28$7.63 85d | -32.9% 76d | Missed | Missed | — | — | +30.4% 9d | Missed |
DROP2025-05-30$11.90 RISE2025-09-19$6.64 PEAK2025-10-09$8.09 132d | -44.2% 112d | Missed | Missed | — | — | +21.8% 20d | Missed |
DROP2025-05-30$11.90 RISE2025-07-21$5.66 PEAK2025-09-04$8.72 97d | -52.4% 52d | Missed | Missed | — | — | +54.1% 45d | Missed |
DROP2025-01-23$11.00 RISE2025-04-01$6.70 PEAK2025-05-30$11.90 127d | -39.1% 68d | Missed | Missed | — | — | +77.6% 59d | Missed |
DROP2025-01-23$11.00 RISE2025-03-03$6.51 PEAK2025-05-21$10.98 118d | -40.8% 39d | Missed | Missed | — | — | +68.7% 79d | Missed |
DROP2024-10-28$9.23 RISE2024-12-20$6.77 PEAK2025-01-23$11.00 87d | -26.7% 53d | Missed | Missed | — | — | +62.5% 34d | Missed |
DROP2024-08-14$9.15 RISE2024-09-25$5.80 PEAK2024-10-28$9.23 75d | -36.6% 42d | Missed | Missed | — | — | +59.1% 33d | Missed |
No scored news yet for a sentiment trend.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Actuate Therapeutics, Inc. announced key initiatives to advance and expand the potential of the elraglusib development program.Actuate is prioritizing the development of the elraglusib oral tablet...
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma,
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapiesCHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immedi
Twice as many advanced pancreascancer patients who received an experimental drug developed byActuate Therapeutics with chemotherapy were alive afterone year as those treated with chemo alone,...
Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in elraglusib arm compared to 4% in control armConsistent survival benefit observed across the poorest prognosis patient subgroups, including those with liver metastases and high disease burden7-40X increases in tumor-infiltrating cytotoxic immune cells and biomarker signals in the elraglusib ar
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $20 to $15.
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 /Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective small-molecule ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS inhibitionPreclinical combination results expected in 2H2026 CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 1
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 2
Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...
Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACTU | -32.67% | -46.13% | -66.99% | -83.03% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -35.64% | -40.42% | -63.55% | -95.71% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 66.0K | $180.92K | 0.00% | Added+17.3% | 2026-03-31 |
| FidelityFMR | fundamental | 8.9K | $24.51K | 0.00% | Added+3094.6% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | Fletcher Aaron G.L. | Director · 10% Owner | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | Huber Martin H. Jr. | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | Keyes Jason A | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | RONNEBERG AMY L | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | Sawhney Roger | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | THOMSON TODD S | Director · 10% Owner | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-05-22 | Zabrowski Dan | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2026-04-01 | LYTLE PAUL J | Chief Financial Officer | A Grant / award(deriv) | 105,000 | — | +$0 |
| 2026-04-01 | Mazar Andrew Paul | Chief Operating Officer | A Grant / award(deriv) | 105,000 | — | +$0 |
| 2026-04-01 | SCHMITT DANIEL M | President, CEO and Director | A Grant / award(deriv) | 237,000 | — | +$0 |
| 2026-02-13 | SCHMITT DANIEL M | President, CEO and Director | M Option exercise(deriv) | 272,055 | — | +$0 |
| 2026-02-13 | SCHMITT DANIEL M | President, CEO and Director | F Tax withholding | 121,874 | $4.33 | −$527.7K |
| 2026-02-13 | SCHMITT DANIEL M | President, CEO and Director | M Option exercise | 272,055 | — | +$0 |
| 2026-01-07 | THOMSON TODD S | Director · 10% Owner | S Open-market sale | 280,000 | $5.80 | −$1.62M |
| 2025-06-30 | Fletcher Aaron G.L. | Director · 10% Owner | P Open-market purchase(deriv) | 71,428 | — | +$0 |
| 2025-06-30 | Fletcher Aaron G.L. | Director · 10% Owner | P Open-market purchase | 71,428 | $7.00 | +$500.0K |
| 2025-06-30 | Kreis Leslie W. | Director · 10% Owner | P Open-market purchase(deriv) | 71,428 | — | +$0 |
| 2025-06-30 | Kreis Leslie W. | Director · 10% Owner | P Open-market purchase | 71,428 | $7.00 | +$500.0K |
| 2025-06-30 | Bios Equity COF, LP | Director · 10% Owner | P Open-market purchase(deriv) | 71,428 | — | +$0 |
| 2025-06-30 | Bios Equity COF, LP | Director · 10% Owner | P Open-market purchase | 71,428 | $7.00 | +$500.0K |
| 2025-05-23 | RONNEBERG AMY L | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2025-05-23 | Keyes Jason A | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2025-05-23 | Fletcher Aaron G.L. | Director · 10% Owner | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2025-05-23 | Zabrowski Dan | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| 2025-05-23 | Sawhney Roger | Director | A Grant / award(deriv) | 15,000 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.20 | — | — |
| 2026-05-14 | -0.21 | -0.24 | -15.66% |
| 2026-03-26 | -0.24 | -0.18 | +26.53% |
| 2025-11-13 | -0.28 | -0.25 | +9.91% |
| 2025-08-14 | -0.31 | -0.30 | +4.76% |
| 2025-05-15 | -0.30 | -0.32 | -5.50% |